ClinicalTrials.Veeva

Menu

Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

V

VA Ann Arbor Healthcare System

Status and phase

Enrolling
Phase 1

Conditions

Non-small Cell Lung Cancer
Liver Metastases

Treatments

Drug: Pembrolizumab
Radiation: Liver SBRT

Study type

Interventional

Funder types

Other
Other U.S. Federal agency

Identifiers

NCT05430009
1652440

Details and patient eligibility

About

Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.

Enrollment

12 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients (≥18 years of age)
  • Histologically or cytologically confirmed NSCLC with liver metastases
  • Eligible for immune checkpoint inhibitors per treating medical oncologist
  • Disease must be measurable per RECIST criteria
  • ECOG Performance status of 0 - 2
  • Adequate organ function per protocol.
  • Allowable prior therapy includes adjuvant durvalumab, prior radiotherapy outside the upper abdomen.
  • Patients must be willing and able to sign an informed consent form.
  • Participants of childbearing potential willing to undergo pregnancy test and use contraception per Appendix.

Exclusion criteria

  • Liver tumor burden which cannot be targeted with SBRT per treating radiation oncologist
  • Presence of uncontrolled intercurrent illness or significant comorbidities precluding participation in a clinical study as determined by investigator
  • Diagnosis of underlying parenchymal end stage liver disease (cirrhosis) or biliary disease (primary biliary cirrhosis).
  • Other invasive malignancy active within 1 years, excluding in situ cancers
  • Presence of psychiatric or substance abuse disorders that would interfere with compliance or safety
  • Has a known history of active Bacillus Tuberculosis (TB), Hepatitis B or Hepatitis C infection
  • Has received a live (active) vaccine within 30 days of enrollment.
  • Active autoimmune disease that has required systemic treatment in the past 1 years aside from hormone replacement therapy (ie. thyroxine, insulin, or physiologic corticosteroid replacement therapy)
  • Baseline corticosteroid use (>10 mg prednisone daily or equivalent) at study entry
  • Pregnancy or breast feeding

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

12 participants in 1 patient group

Arm 1
Experimental group
Description:
This is an open-label, single-arm, single center clinical trial to evaluate the feasibility of liver SBRT (up to 4 metastases) during the first cycle of physician's choice ICI for NSCLC.
Treatment:
Radiation: Liver SBRT
Drug: Pembrolizumab

Trial contacts and locations

1

Loading...

Central trial contact

Michael Green, MD; Shaneta Waddy, MHA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems